top of page
Asian women having a chat after workout
Cervical Health

Today's gold standard in liquid-based cytology testing, the Hologic ThinPrep Pap test was introduced in 1996. Since then, it contributed to a further 28% reduction in invasive cervical cancers in the United States thanks to its great improvement upon conventional Pap technology.

 

Aptima HPV assay is HSA approved and specifies intended uses as a first-line primary screening test for women, for reflex testing of abnormal Pap test results for women and for adjunctive testing together with cervical cytology (co-testing).*

 

Continuing to advance cervical health is a hallmark of Hologic. It now offers a full range of highly specific testing solutions proven to reduce false negatives and false positives, giving physicians the confidence to identify patients at high risk for developing cervical cancer, while minimizing unnecessary interventions.

 

*Aptima HPV Assay [package insert, AW-14517-001 Rev 001 (EN)], San Diego, CA; Hologic, Inc., 2017.

Leading cervical cancer screening

For over 20 years, Hologic has been at the forefront of cervical cancer screening. Pap and human papillomavirus (HPV) testing are an essential component of their efforts in women’s health. With more than 650 million tests performed worldwide (1), their ThinPrep® Pap test has become the most widely used liquid-based cytology test (1)—helping healthcare providers detect the presence of abnormal cervical cells (2). While other HPV assays target DNA, the Aptima® HPV assays identify high-risk HPV mRNA that is indicative of the HPV infections most likely to lead to cervical disease. Furthermore, our Aptima HPV 16 18/45 genotype assay allows for the detection of HPV types 16, 18, and 45, which together are associated with over 75% of all cancers and 94% of adenocarcinomas (3).

Aptima® HPV test

Aptima HPV.jpg

ThinPrep® Pap Test

image_14.jpg

Aptima® HPV 16/18/45 genotype test 

genotype.jpg
References
  1. Hologic, Inc. Data on File. 

  2. ThinPrep 2000 Processor [instructions for use]. MAN-02624-001, Rev. 005. Marlborough, MA: Hologic, Inc.; 2017.

  3. De Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet. 2010;11(11):1048-56. doi:10.1015/S1470-2045(10)70230-8.

Contact Us

Thanks for submitting!

Laboratory Scientist
Contact Form
bottom of page